FTSE 100: Index falls as earnings results weigh; pound below $1.33, Bodycote soars
In a challenging market environment, Henry Schein , Inc. (HSIC) stock has touched a 52-week low, dipping to $63.66. According to InvestingPro data, the company maintains a "GOOD" Financial Health score, with particularly strong marks in profitability metrics. This latest price level reflects a notable decline for the global healthcare products and services provider, with a -8.64% return over the past year. While nine analysts have recently revised earnings downward, the company’s management has been actively buying back shares. Investors are closely monitoring the company’s performance, with its strong free cash flow yield and $12.67 billion in revenue suggesting resilience despite market pressures. InvestingPro offers 5 additional key insights about HSIC’s market position and future prospects. Henry Schein’s movement in the market will be watched with interest as stakeholders consider the company’s strategies to navigate through the current economic headwinds, particularly given its historically low price volatility and solid current ratio of 1.42.
In other recent news, Henry Schein Inc (NASDAQ:HSIC). reported its Q4 2024 earnings, revealing a slight miss in both earnings per share (EPS) and revenue against market forecasts. The company’s EPS was $1.19, below the expected $1.23, while revenue reached $3.19 billion, falling short of the forecasted $3.35 billion. Despite these misses, the company demonstrated solid performance with global sales reflecting a 5.8% growth year-over-year. Additionally, Henry Schein announced changes in its executive team, with President James P. Breslawski stepping down in April 2025 to become a Senior Advisor.
Mizuho (NYSE:MFG) Securities recently adjusted its outlook on Henry Schein, cutting the stock price target from $78 to $76 while maintaining a Neutral rating. This adjustment reflects changes in the company’s business segmentation and updated earnings guidance. Notably, the company’s dental implant franchise is experiencing growth in Europe and stability in the U.S., which is attributed to general practitioners expanding their services. The Medical (TASE:BLWV) segment is also benefiting from a strong flu season and a robust home health market.
Furthermore, Henry Schein disclosed a significant change in its executive team through an SEC filing, indicating that James P. Breslawski will transition to a new role. Investors are likely to watch for further announcements to understand the implications of this executive shift. These developments come as Henry Schein continues to focus on innovation and strategic acquisitions to drive growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.